Pneumonia is the leading cause of death from infection in the developed world. In recent years, researchers and healthcare professionals have worked tirelessly to address this issue. Multiresistance is a significant problem in severe pneumonia, so it is crucial to select the appropriate antibiotic at the correct dose and via the appropriate route of administration to ensure effective concentrations in the lung parenchyma. The diagnosis of pneumonia can also be challenging, so it is vital that imaging techniques, biomarkers, and microbiological methods are employed properly. An appropriate therapeutic approach is vital for managing severe community-acquired pneumonia, as it can be complex and is key to achieving optimal clinical outcomes. Nosocomial pneumonia also requires optimal management to avoid therapeutic failure and to improve outcomes, particularly in post-surgery patients. Not only bacteria, but also viruses and fungi can cause severe pneumonia, and appropriate diagnosis is essential for proper treatment. Finally, the correct use of new antimicrobial molecules can help to improve the clinical outcomes of these patients. To provide an update on these issues, a multidisciplinary team of Spanish experts met at the Seventh Annual Pneumonia Day Meeting, which was sponsored by the Grupo de Estudio de Infección en el Paciente Crítico (GEIPC) of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). This paper summarises the discussions held at the meeting and offers the latest insights on these topics, providing guidance on overcoming the challenges associated with pneumonia management.
Rodríguez-Leal et al. (Fri,) studied this question.